Product Images Estradiol

The NDC 69238-1447-1 Estradiol Transdermal System, USP, delivers 0.025 mg/day of estradiol for hormone replacement therapy. Each 1.89 cm2 system contains 0.314 mg of estradiol, USP, and has an acrylic and silicone adhesive backing for skin application. The package is not child-resistant, and the system should be applied immediately upon removal from the pouch and stored between 20°C to 25°C (68°F to 77°F). This particular brand is distributed by Amneal Pharmaceuticals LLC in Bridgewater, NJ.*

This is a product description for a transdermal patch containing estradiol, a type of estrogen hormone. Each system contains 0.314 mg of USP estradiol and inactive ingredients including an acrylic adhesive, polyethylene vinylacetate, and various alcohols. The patch is intended for transdermal use only, applied twice-weekly, and should be stored at room temperature between 20-25°C. The given text also includes codes and instructions for use.*

This is a medication called Estradiol Transdermal System, USP designed to deliver a 0.0375 mg/day dosage. Each package contains one 2.83 cm² system that contains 0.470 mg of estradiol USP along with inactive components such as an acrylic adhesive, silicone adhesive, oleyl alcohol, dipropylene glycol, povidone, polyester and ethylene vinyl acetate copolymer film, and polyester release liner. This medication should be kept out of reach of children and applied immediately upon removal from the pouch. It should not be stored unpouched and stored at a controlled temperature range of 20-25°C (68-77°F). This product is distributed by Amneal Pharmaceuticals LLC.*

This is a description of a transdermal patch product called "Estradiol Transdermal System, USP 0.0375 mg/day" distributed by Amneal Pharmaceuticals LLC. The product is for transdermal use only and should be applied twice-weekly. The packaging contains 8 systems. The inactive components include okylakohol, diropylens g et acetate copol. Dosage and administration instructions are available in the package insert. The text also includes some gibberish and a list of possible keywords such as "swasshg," "puuy," and "Ajuo xy aley."*

This is a description of the NDC 69238-1295-1 Estradiol Transdermal System that delivers 0.05mg/day of estradiol via a 3.78 cm² system. The system contains 0.627 mg of estradiol, and the inactive components include acrylic adhesive, silicone adhesive, oleyl alcohol, dipropylene glycol, povidone, polyester, and ethylene vinyl acetate copolymer film, polyester release liner. The package is not child-resistant, and the Estradiol Transdermal System must be applied immediately after removal from the pouch and should not be stored unpouched. The product should be stored at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). This product is distributed by Amneal Pharmaceuticals LLC, based in Bridgewater, New Jersey.*

This is a package insert for Transdermal Estrac system manufactured by Amneal Pharmaceuticals LLC. It is a USP system that contains 0.05 mg of estraol and is meant for transdermal use only. The package contains 8 systems and each 3.78 cm system contains 0.627 mg of estraol, USP. The dosage and administration recommended is to apply twice-weekly. The text contains a lot number and expiration date.*

This is a description of a product that has three components: a backing, an adhesive containing estradiol, and a protective liner. However, without additional context, it is not clear what this product is or what its purpose is.*

This is a prescription medication labeled NDC 69238-1294-1 containing 0.075 mg/day of estradiol, USP. It is designed as a 5.66 cm² system to be applied immediately upon removal from the pouch. The medication contains several inactive components such as acrylic adhesive, silicone adhesive, oleyl alcohol, dipropylene glycol, povidone, polyester, and ethylene vinyl acetate copolymer film. The package is not child-resistant and should be kept out of reach from children. The medication should be stored within a range of 20°C to 25°C and should not be stored unpouched. The medication is distributed by Amneal Pharmaceuticals LLC located in Bridgewater, NJ 08807. The expiration date is not available in the text.*

This is a description of a pharmaceutical product. It includes a patch with 8 systems. Each system contains 0.340 g of estradiol and some inactive components. It is for transdermal use only and has to be kept out of reach of children. The patch should be applied twice weekly and should not be stored unpouched. The package insert should be consulted for dosage and administration. It is distributed by Amneal Pharmaceuticals LLC.*

This is a prescription medication containing 0.1 mg/day of estradiol USP that is delivered through a 7.55 cm² system. The system contains an acrylic and silicone adhesive, oleyl alcohol, dipropylene glycol, povidone, polyester and ethylene vinyl acetate copolymer film, as well as a polyester release liner. It is important to keep the packaging away from children and to apply the system immediately after removal from the pouch. It should be stored at 20-25°C (68-77°F), with excursions permitted to 15-30°C (59-86°F). This medication is distributed by Amneal Pharmaceuticals LLC.*

This is a description of a transdermal patch that contains 0.1 mg/day of Estradiol USP. The patch is for transdermal use only and is applied twice weekly. It contains several inactive components including acrylic adhesive, polyester, and Westrel (details not provided). The package is not child-resistant, and users are instructed to keep it out of reach of children. The transdermal patch should not be stored unpouched and should only be used within the recommended temperature range. The manufacturer is Amneal Pharmaceuticals LLC, and the product is distributed under different brands.*

This appears to be a report on a medical study. It indicates that a reduction from baseline was observed for a group (possibly related to dosage) that received Vivelle at 0.0375 mg/day. The results are compared to placebo and appears to show statistical significance (p<0.05). However, without more context it is not clear what condition or symptoms were being treated in the study.*